Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
Current Medical Research and Opinion|August 31, 2019
Systematic review and network meta-analysis of the efficacy and safety of lidocaine 700 mg medicated plaster vs. pregabalinTitas Buksnys, Nigel Armstrong, Gill Worthy, et al.
Pharmacoeconomics|February 1, 2023
Filgotinib for Treating Moderately to Severely Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology AppraisalAntoinette D I van Asselt, Nigel Armstrong, Merel Kimman, et al.
Pharmacoeconomics|October 8, 2018
Nivolumab for Treating Metastatic or Unresectable Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology AppraisalSabine E Grimm, Nigel Armstrong, Bram L T Ramaekers, et al.
Pharmacoeconomics|January 19, 2018
Ticagrelor for Secondary Prevention of Atherothrombotic Events After Myocardial Infarction: An Evidence Review Group Perspective of a NICE Single Technology AppraisalXavier G L V Pouwels, Robert Wolff, Bram L T Ramaekers, et al.
Pharmacoeconomics|December 10, 2019
Durvalumab for the Treatment of Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology AppraisalWillem J A Witlox, Antoinette D I van Asselt, Robert Wolff, et al.
Clinical Chemistry|January 8, 2021
Optimizing the Use of High-Sensitivity Troponin Assays for the Early Rule-out of Myocardial Infarction in Patients Presenting with Chest Pain: A Systematic ReviewMarie E Westwood, Nigel Armstrong, Gill Worthy, et al.
Health Technology Assessment (Winchester, England)|October 27, 2020
Avatrombopag and lusutrombopag for thrombocytopenia in people with chronic liver disease needing an elective procedure: a systematic review and cost-effectiveness analysisNigel Armstrong, Nasuh Büyükkaramikli, Hannah Penton, et al.
Pharmacoeconomics|November 9, 2019
Fluocinolone Acetonide Intravitreal Implant for Treating Recurrent Non-infectious Uveitis: An Evidence Review Group Perspective of a NICE Single Technology AppraisalXavier G L V Pouwels, Svenja Petersohn, Vanesa Huertas Carrera, et al.
Pharmacoeconomics|February 9, 2023
Pralsetinib for RET Fusion-Positive Advanced Non-small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology AppraisalMohamed N M T Al Khayat, Nigel Armstrong, Jeremy Howick, et al.
Pharmacoeconomics|November 4, 2020
Lenalidomide with Rituximab for Previously Treated Follicular Lymphoma and Marginal Zone Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology AppraisalWillem J A Witlox, Sabine E Grimm, Rob Riemsma, et al.
Pageof 6